Background
Cardiovascular disease resulting from poor blood pressure (BP) control is a leading cause of death globally [1, 2] . Up to 13.5% of premature deaths -or 7.6 million deaths worldwide annually -are attributed to suboptimal control of arterial hypertension [3, 4] . Europeans are among those with the highest systolic BP (SBP) in the world and thus are at higher risk of end-organ damage [5] . Achieving guideline-recommended BP targets [6, 7] is difficult in general [8] [9] [10] and an even greater challenge in patients with established cardiovascular and/or renal disease (ECVRD) [6] [7] [8] . The European Society of Hypertension/European Society of Cardiology (ESH/ESC) guidelines for the management of hypertension [11, 12] classify patients with ECVRD as having a 'very high added ' 10-year risk for (additional) cardiovascular events. Identifying determinants of BP outcomes in patients with ECVRD and how these may be different from those in patients without ECVRD is critical to effective hypertension management and prevention of further cardiovascular and renal disease.
We report here on subgroup analyses for 1107 patients with and 2087 patients without ECVRD who were included in the Belgian PREVIEW study by 504 general practitioners (GPs) [13] . PREVIEW was a prospective pharmacoepidemiological multicentre study that examined determinants and predictors of BP reduction and control following 90-day second-line treatment with the angiotensin II receptor blocker (ARB) valsartan. The purpose of the subgroup analyses was fourfold: to examine whether there were significant differences in patient characteristics, antihypertensive treatment and BP values and control at 90 days in patients with and without ECVRD; to quantify the proportions of variance in BP outcomes at 90 days attributable to physician-level versus patient-level factors; to identify the multilevel (patients 'nested') determinants of BP values at 90 days in these two subsamples; and to identify independent predictors of uncontrolled BP at 90 days in both subsamples.
Methods
The methodology of the PREVIEW study is described in detail in the article reporting the results for the entire sample, as are data on the physician sample, including knowledge of and practice according to evidence-based hypertension guidelines [13] . Elements of relevance are summarized below.
Design
PREVIEW was designed as a 90-day prospective multicentre multilevel (patients 'nested' under physicians) pharmacoepidemiological study of the effectiveness of valsartancentric antihypertensive regimens and the determinants thereof, in patients in whom prior treatment had failed or was not tolerated. A total of 3194 hypertensive patients (SBP ≥ 140 mmHg and/or DBP ≥ 90 mmHg; SBP ≥ 130 mmHg and/or DBP ≥ 80 mmHg for diabetic patients) treated by 504 general practitioners in Belgium were started on a valsartan-centric regimen in accordance with their physician's best clinical judgment and re-evaluated 90 days later.
Samples for subgroup analyses
Patients were considered to have ECVRD if they presented at baseline with at least one of the following cardiovascular and/or renal conditions comorbid to their arterial hypertension: myocardial infarction; angina pectoris; coronary revascularization; heart failure; ischaemic or haemorrhagic cerebrovascular accident; transient ischaemic attacks; intermittent claudication; peripheral bypass/stent or amputation; or diabetic nephropathy or any other nephropathies as evidenced by creatinine greater or equal to 1.5 mg/dL and/or proteinuria. The subsamples consisted of patients whose treating physician had decided independently, according to best clinical judgment and within the approved label and reimbursement regulations, to prescribe one of three formulations of valsartan (80 mg, 160 mg or 80 mg/12.5 mg hydrochlorothiazide) as secondline monotherapy or combination therapy because first-line therapy had failed or was not tolerated. Patients with known sensitivity to ARBs or hydrochlorothiazide were excluded, as were patients concomitantly treated with an ARB other than valsartan.
Data model

Physician questionnaire
The physician questionnaire comprised: practice type, location/setting and patient mix; demographics; sources of information and knowledge related to hypertension; hypertension management practices; prescription patterns; management of adverse effects; SBP/DBP thresholds for treatment initiation and intensification; perceptions of patient adherence; and knowledge of practice guidelines.
Baseline patient data
The baseline patient data acquired were as follows: demographics; hypertension and cardiovascular history; comorbidities; lifestyle; prior antihypertensive medications; SBP and DBP; clinical data; starting valsartan dose; class of concomitant antihypertensives; and patient-reported number of days they had been non-adherent in the preceding 4 weeks.
Patient follow-up data
The patient follow-up data acquired after 90 days were as follows: SBP and DBP; concomitant drug(s) taken or changed since previous visit; clinical data; patient-reported number of days they had been non-adherent in the preceding 4 weeks; changes in valsartan dose since previous visit; and adverse effects over the past 90 days.
GPs were asked to measure BP three times at 1 to 2min intervals in a sitting position after 5 min of rest using a calibrated standard sphygmomanometer and appropriatelysized cuff placed at heart level [14] . The mean of the three sitting measurements without rounding was recorded as the SBP and DBP.
Statistical analysis
Standard descriptive statistics were used to describe the subsamples, including proportions and appropriate measures of central tendency and dispersion. Comparisons between subsamples were made using independent sample t tests, corrected as necessary for unequal variances, or Pearson's or Yates's 2 tests (contingency corrected) or Fisher's exact test where appropriate.
We hypothesized that BP outcomes in each subsample were related to physician-and patient-level variables. Each participating physician recruited several patients; therefore patients could not be considered independent but instead 'nested' under their treating physician. We assumed that the n j patients recruited by physician j might share some proportion of variance in BP values attributable to their common physician and that this physician's influence might impact BP values prior to any patient-specific variables. Accordingly, we applied two-level hierarchical linear and logistic modelling for each subsample [15] . The intraclass correlation coefficient (ICC) quantified the variability in patient outcome attributable to within-physician variability before any patient-level determinants were considered. Likelihood-ratio tests were performed to determine if the physician-level ICC was significantly greater than zero. Adjusted slope coefficients or odds ratios and 95% confidence intervals (CI) were calculated to estimate the direction and strength of the relationship between individual factors and BP values and control. The ESH/ESC and Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC-7) guidelines for BP control (140/90 mmHg for non-diabetics; 130/80 mmHg for diabetics) [6, 7] were used to determine controlled versus uncontrolled BP. Statistical significance was set at P < 0.05, with corrections for multiplicity applied as necessary.
Results
Patient characteristics, medical history and clinical status at baseline
Of the 3194 patients with evaluable data, 1107 (35.9%) had ECVRD whereas 2087 (64.1%) did not. Compared with patients without ECVRD, patients with ECVRD tended to be older, male and living alone ( Table 1) . A larger proportion of patients with ECVRD had significant risk factors at baseline, including lack of physical exercise, dyslipidaemia, diabetes, elevated C-reactive protein and family history of early cardiovascular disease. These patients had been treated for hypertension longer, with more classes of antihypertensives and with more prior antihypertensive medication changes. Their SBP and DBP at the time of enrollment were slightly but significantly lower compared with patients without ECVRD. Both groups had statistically similar proportions of patients who admitted to having been non-adherent to their antihypertensive medication prior to enrolment in the study.
Evolution of BP from baseline to follow-up
At 90 days, mean SBP was not statistically different between the two groups, but mean DBP was lower among patients with ECVRD (Table 2) . Mean SBP and DBP at followup were statistically similar between diabetic patients with and without ECVRD, but were higher among nondiabetic patients without ECVRD. Mean absolute changes in mmHg from baseline to follow-up were statistically similar among patients with and without ECVRD in general and stratified by diabetic status. BP control rates at baseline were not statistically different between the ECVRD and non-ECVRD groups in general and stratified by diabetic status. At follow-up, the proportions of patients with controlled SBP, DBP and combined SBP/DBP were higher among patients without ECVRD in general, although these differences were not evident when stratified by diabetic status.
Attribution of variance to physician class effect
Blood pressure values at 90 days Among patients with ECVRD, 25.5% of the variance in SBP at follow-up was attributable to a physician class effect (ICC 0.255, 95% CI 0.189-0.331; P < 0.001), similar to that observed for patients without ECVRD (ICC 0.257, 95% CI 0.212-0.306; P < 0.001). The corresponding DBP percentages of attributable variance were 28.1% for patients with ECVRD (ICC 0.281, 95% CI 0.214-0.35; P < 0.001) and 24.6% for patients without ECVRD (ICC 0.246, 95% CI 0.202-0.295; P < 0.001).
Blood pressure control at 90 days
Among patients with ECVRD, a physician class effect accounted for 20.7% (ICC 0.207, 95% CI 0.123-0.329; P < 0.001) and 19 Table 3 presents the hierarchical linear models for SBP and DBP values at 90 days for the ECVRD and non-ECVRD groups. Table 4 summarizes the hierarchical logistic models for SBP, DBP and combined SBP/DBP control for patients with and without ECVRD. Table 5 summarizes the variables retained in the five models for each group, indicating whether a patientor physician-related determinant increased or decreased SBP or DBP at 90 days or increased or decreased the odds of uncontrolled SBP, DBP and combined SBP/DBP at 90 days, stratified by ECVRD status.
Modelling of blood pressure values and control at follow-up
Patient-related variables retained in three or more models included age, lack of regular physical exercise, being highly vulnerable to uncontrolled BP, concomitant treatment with a ␤-adrenergic blocker and non-adherent days in the past 4 weeks. Less frequently retained variables included living alone, obesity, family history of premature cardiovascular disease, days elapsed since most recent BP measurement, C-reactive protein greater or equal to 1 mg/dL and being treated with 80 mg valsartan (versus higher doses) and/or an angiotensin-converting enzyme inhibitor concomitantly. As to physician-related variables, years in practice and the number of clinical practices that were concordant with best practice guidelines were included in three or more models; this refers to hypertensive treatment practices reported by physicians that were in accordance with the prevailing ESH/ESC guidelines. Retained less frequently were the number of hypertension patients seen in the past 12 months, the median duration of the first visit with a newly-diagnosed hypertension patient or a visit for titrating antihypertensive medication and the 
Discussion
This subgroup analysis comparing 1107 patients with and 2087 patients without ECVRD yielded five principal findings. First, both groups had different profiles in terms of demographics, cardiovascular risk factors, hypertension history and past and current antihypertensive treatment, indicating that ECVRD is a clinically relevant differentiator of hypertensive patient mix. Second, as to BP outcomes, there were only slight differences between groups in BP values at 90 days and absolute change in BP from baseline to follow-up, suggesting that BP reduction can be achieved in patients with and without ECVRD. Third, fewer patients with ECVRD achieved BP targets than did patients without ECVRD; hence, ECVRD can be considered as a warning signal for antihypertensive treatment failure. Fourth, physicianlevel class effects explained between 15.0% and 28.1% of the variance in BP outcomes before patient-level factors were considered; this confirms percentages observed in other studies on valsartan that we have conducted [16] . Lastly, despite some convergence, the multilevel determinants of BP values and the logistic likelihood of BP control varied considerably between hypertensive patients with and without ECVRD; this underscores that antihypertensive treatment with valsartan should carefully consider patientand physician-related variables that may influence differential outcomes in patients with ECVRD.
Considering that patients with ECVRD were older, more likely to be male, had a higher prevalence of most risk factors and all indices of advanced pathology, had been diagnosed with hypertension longer and had more complex prior antihypertensive treatment than patients without ECVRD, it is remarkable that only 5% fewer of them achieved 90-day SBP control (35.1% and 40.5%, respectively) and combined SBP and DBP control (31.4% and 36.0%, respectively) than patients without ECVRD. Thus, these data provide evidence of the effectiveness of valsartan as a second-line antihypertensive agent in patients with and without ECVRD. The results may also be due, partially, to the fact that more patients with ECVRD were treated with each class of concomitant antihypertensive agent in addition to valsartan than patients without ECVRD; this may reflect the greater antihypertensive treatment complexity for these patients than for patients with a lower global cardiovascular risk [6, 7, 11] .
Several determinants of SBP and DBP values and predictors of lack of SBP, DBP and SBP/DBP control at 90 days merit further discussion. These determinants fall into three categories: non-modifiable variables, manageable conditions and modifiable risk factors. The non-modifiable variables serve an important alert function. In addition to older age being associated with higher SBP but lower DBP, hypertension management in older adults is characterized by an even greater sensitivity to severe diabetes (as evidenced by advanced retinopathy), a complexity of antihypertensive regimens used in attempts to bring BP under control, and cardiovascular risk [17] . Sex was not retained as a determinant despite other evidence that BP control may be more difficult to achieve in women and differences in determinants of BP outcomes between women and men [18] . Living alone was retained in one model and may refer more generally to a lack of social support [19] . The influence of a family history of premature cardiovascular disease on BP outcomes underscores the interaction between this risk factor and patients' current ECVRD.
Diabetes had the single most influential impact on BP outcomes and severely compromises the likelihood of achieving BP control. Baseline variables as well as the variables retained in the models point more broadly at the negative impact of metabolic syndrome on BP values and BP control, especially among patients with ECVRD but also among patients without ECVRD. Diabetes and metabolic syndrome are manageable conditions and our findings underscore the importance of aggressive diabetes treatment but also, more comprehensively, the constituent elements of metabolic syndrome (weight, lipids and blood pressure) and their associated risk factors [20] . Relatedly, fitting the heuristic profile of high vulnerability to uncontrolled hypertension [21] was consistently associated with increased BP values and decreased BP control, the effects being more pronounced among patients with ECVRD. The modifiable variables found to impact on BP outcomes, especially among patients with ECVRD, are behavioural. Exercise regimens must be developed for patients under consideration of whether or not they have ECVRD, to optimize the BP-lowering effect of physical activity [22] [23] [24] . Low adherence decreases the outcomes of medication treatment by 26%. Our subanalyses underscore how BP values rise and BP control declines for every day of non-adherence in the preceding 4 weeks. GPs must be provided with rapid if not intuitive methods of assessing adherence that can be integrated seamlessly into the clinical visit and patients must be counselled to be adherent and provided with tools enabling better medication behaviour. A known determinant of non-adherence is the complexity of the medication regimen and our findings confirm this, in particular among patients with ECVRD [25] . Focusing on these three categories of determinants of BP outcomes may go a long way towards overcoming the 'hypertension paradox' identified by Chobanian [26] , which states that despite therapeutic advances, rates of uncontrolled BP keep rising. Our studies continue to underscore the influence of clinicians in successful hypertension management and this may be an integral part of the solution to the hypertension paradox [16] . Physician-level factors improved BP outcomes in general but especially among patients with ECVRD. Managing hypertension in congruence with evidence-based guidelines is critical, as is exposure to a high volume of patients with hypertension. Yet, so is physician vigilance -although this was not demonstrated directly but, as in our prior studies, paradoxically, in terms of number, type and duration of visits and interval of BP measurement [16] . On the other hand, how long one has been practicing tends to lead to poorer BP outcomes [16, 25] . Hence, it is not surprising that up to 28.1% of BP outcomes were attributable to the treating physician, confirming similar proportions observed in other analyses [16] .
The limitations of the PREVIEW study, its subanalyses and related studies have been identified elsewhere [13, 16, 27] , as have directions for future research. Limitations include the study being conducted in only one country, not being population-based, focusing only on valsartan and not other ARBs and not being an effectiveness randomized controlled trial but an effectiveness observational study. The subanalyses here employed a post hoc-defined binary measure of ECVRD; future studies are needed to evaluate the role of an a priori operationalized ECVRD gradient on BP outcomes following antihypertensive treatment. In this regard, it might be helpful to examine the interaction of established cardiovascular and established renal disease, not just as singular or joint presences.
Conclusion
We examined the multilevel determinants of 90-day BP values and control in 1107 hypertensive patients with ECVRD and 2087 without ECVRD being treated with valsartan as part of the Belgian PREVIEW study. A greater proportion of patients without ECVRD had controlled SBP and DBP at 90 days compared with patients with ECVRD. Many of the patient-and physician-level determinants of BP by ECVRD subpopulation are amenable to intervention and the remainder can serve as warning signs that patients may remain vulnerable to poor outcomes associated with suboptimal BP control. ECVRD patients present with differential characteristics, conditions and determinants that mandate individualized attention to complement general evidencebased antihypertensive treatment. 
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